|Bid||5.88 x 800|
|Ask||5.99 x 1400|
|Day's range||5.64 - 6.10|
|52-week range||2.01 - 6.34|
|Beta (5Y monthly)||-0.55|
|PE ratio (TTM)||N/A|
|Earnings date||10 Nov 2021 - 15 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Investors need to pay close attention to BELLUS Health (BLU) stock based on the movements in the options market lately.
LAVAL, Quebec, September 13, 2021--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced positive findings from a preplanned administrative interim analysis of the ongoing Phase 2b SOOTHE trial of BLU-5937, the Company’s highly selective P2X3 antagonist, in patients with refractory chronic cou
If you want to know who really controls BELLUS Health Inc. ( TSE:BLU ), then you'll have to look at the makeup of its...